Sarah A. Teichmann

CIK: 0002030916

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TXG

10x Genomics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

TXG
10x Genomics, Inc.
Aug 14, 2026
Sale(S)
Direct
2.3K shares at avg. $57.15$130K
TXG
10x Genomics, Inc.
Aug 13, 2026
Sale(S)
Direct
5.3K shares at avg. $57.29$302K
TXG
10x Genomics, Inc.
Jun 4, 2026
Award(A)
Direct
8.8K shares-
TXG
10x Genomics, Inc.
Feb 25, 2026
Sale(S)
Direct
7.6K shares at avg. $19.41$147K
TXG
10x Genomics, Inc.
Jun 3, 2025
Award(A)
Direct
15.4K shares-
TXG
10x Genomics, Inc.
Aug 30, 2024
Award(A)
Direct
19K shares-

		Type	Shares	Price		Ownership
Aug 14, 2026	TXG 10x Genomics, Inc.	Sale(S)	2,273	$57.15	$129,902	Direct
Aug 13, 2026	TXG 10x Genomics, Inc.	Sale(S)	5,278	$57.29	$302,377	Direct
Jun 4, 2026	TXG 10x Genomics, Inc.	Award(A)	8,829	-	$0	Direct
Feb 25, 2026	TXG 10x Genomics, Inc.	Sale(S)	7,579	$19.41	$147,108	Direct
Jun 3, 2025	TXG 10x Genomics, Inc.	Award(A)	15,357	-	-	Direct
Aug 30, 2024	TXG 10x Genomics, Inc.	Award(A)	19,002	-	$0	Direct

1-6 of 6 transactions

About Teichmann Sarah A.

Teichmann Sarah A. (SEC CIK 0002030916) files insider reports with the SEC as Director of 10x Genomics, Inc. (TXG).

Signal8 holds 5 ownership filings by Teichmann Sarah A., all Form 4s, filed between Sep 4, 2024 and Aug 17, 2026. Those filings report 6 transactions, from Aug 30, 2024 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Teichmann Sarah A.'s filings is in PLEASANTON, CA.

Recent filings by Teichmann Sarah A.

Aug 14, 2026: Open-market sale of TXG shares (Form 4, code S).
Aug 13, 2026: Open-market sale of TXG shares (Form 4, code S).
Jun 4, 2026: Grant or award of TXG shares (Form 4, code A).
Feb 25, 2026: Open-market sale of TXG shares (Form 4, code S).
Jun 3, 2025: Grant or award of TXG shares (Form 4, code A).

Other insiders filing for 10x Genomics, Inc. (TXG)

SULIMAN SHEHNAAZ, Director
Saxonov Serge, Chief Executive Officer
Taich Adam, Chief Financial Officer
STUELPNAGEL JOHN R, Director
Hindson Benjamin J.
Popovits Kimberly J, Director

How to read Form 4 transaction codes